Merus Stock Price, News & Analysis

Merus (Nasdaq: MRUS) announced acceptance of two abstracts on petosemtamab (MCLA-158) for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct 22-26, 2025 in Boston.

Interim data from a Phase 2 trial evaluating petosemtamab as monotherapy in heavily pretreated (3L+) metastatic colorectal cancer and combined with standard chemotherapy in 1L and 2L mCRC will be presented in Plenary Session 4 on Friday, Oct 24, 10:00-11:40 a.m. ET. A poster on preclinical effects against cancer stem cells will be presented the same day, 12:30-4:00 p.m. ET. Abstracts appear in the conference app on Oct 22, 12:00 p.m. ET, and full presentations are planned to be posted on Merus' website at session start.

Genmab (Nasdaq: GMAB) has announced its plans to acquire Merus (Nasdaq: MRUS) in an all-cash transaction valued at approximately USD 8.0 billion, or USD 97.00 per share. The acquisition represents a 41% premium over Merus' closing price on September 26, 2025.

The strategic acquisition brings petosemtamab, a late-stage oncology asset with two FDA Breakthrough Therapy Designations for head and neck cancer, into Genmab's portfolio. The Phase 3 asset showed promising Phase 2 data at ASCO 2025, with superior overall response rates and progression-free survival compared to standard care. Genmab expects potential product launch in 2027, with projected annual sales of $1+ billion by 2029.

The transaction will be funded through cash and $5.5 billion in non-convertible debt. Genmab aims to achieve gross leverage below 3x within two years post-closing. The deal is expected to close by early Q1 2026 and become EBITDA accretive by end of 2029.

Merus (NASDAQ:MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, announced its participation in the upcoming 2025 Wells Fargo Healthcare Conference. Bill Lundberg, M.D., President and CEO, will engage in a fireside chat on September 4, 2025, at 3:45 p.m. ET.

The presentation will be accessible via webcast on the company's Investors webpage, with a recording available for limited time afterward.

Merus (NASDAQ: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. Bill Lundberg, M.D., the company's President and CEO, will engage in a fireside chat on Wednesday, August 13, 2025, at 1:30 p.m. ET.

The presentation will be available via webcast on the Investors section of Merus's website, with an archived version accessible for a limited time following the event.

Merus (NASDAQ:MRUS) reported significant Q2 2025 results and clinical progress. Their lead drug petosemtamab with pembrolizumab showed a 63% response rate in 43 evaluable head and neck cancer patients, with 79% overall survival at 12 months. The company successfully completed a $345M public offering, extending cash runway into 2028 with $892M in cash and equivalents.

Two phase 3 trials for petosemtamab in head and neck cancer are expected to be substantially enrolled by YE25, with potential topline interim readouts in 2026. The drug received Breakthrough Therapy Designation from FDA for first-line PD-L1+ HNSCC treatment. Initial clinical data for colorectal cancer is planned for 2H25.

Q2 financials showed increased R&D expenses of $93.9M, up $44.8M year-over-year, primarily due to clinical trial expansion. Revenue increased by $1.5M compared to Q2 2024, driven by collaboration partnerships.

Merus N.V. (NASDAQ: MRUS), an oncology company specializing in multispecific antibody therapeutics, has granted stock options to two new employees as inducement awards. The options, approved on August 1, 2025, allow the purchase of up to 240,000 shares at an exercise price of $65.56 per share.

The options have a ten-year term and vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over three years. These grants were made outside the Company's 2016 Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Merus N.V. (MRUS) has announced the pricing of a public offering of 5,263,158 common shares at $57.00 per share, aiming to raise approximately $300.0 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to an additional 789,473 shares. The offering is expected to close around June 5, 2025. Merus plans to use the net proceeds to advance clinical development of its product candidates, fund preclinical research and technology development, and support working capital and general corporate purposes. The offering is being led by multiple joint book-running managers including Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital, with Van Lanschot Kempen acting as lead manager.

Merus N.V. (MRUS), an oncology company specializing in multispecific antibodies and antibody drug conjugates, has announced a proposed public offering of common shares. The offering includes a 30-day option for underwriters to purchase up to an additional 15% of shares. The company plans to use the proceeds to advance clinical development of product candidates, fund preclinical research, and support working capital needs. The offering is being managed by multiple firms including Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital as joint book-running managers, with Van Lanschot Kempen as lead manager. The offering will be conducted through a shelf registration statement on Form S-3 filed with the SEC.

Merus N.V. (Nasdaq: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced upcoming presentations at two major investor conferences. CEO Bill Lundberg will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 9:40 a.m. ET and the Jefferies Global Healthcare Conference on June 4 at 3:10 p.m. ET. The presentations will be available via webcast on the company's Investors page, with recordings accessible for a limited time afterward.